ArriVent BioPharma (AVBP) earnings
In the quarter ended June 2026, ArriVent BioPharma had revenue of —, and diluted EPS of -1.05.
On August 12, 2026 it reported EPS of -1.05 against an estimate of -0.98 (missed).
The next report is expected on Monday, November 9, 2026, with EPS expected around -1.07.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Mon Nov 9, 2026 | — | -1.07 | — |
| Last | Wed Aug 12, 2026 | — | -0.98 | -1.05 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from ArriVent BioPharma's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | — | — | -1.05 | — | — | 2026-08-12 |
| Mar 31, 2026 | — | — | -0.96 | — | — | 2026-05-11 |
| Dec 31, 2025 | — | — | — | — | — | 2026-03-05 |
| Sep 30, 2025 | — | — | -0.83 | — | — | 2025-11-10 |
| Jun 30, 2025 | — | — | -0.90 | — | — | 2025-08-11 |
| Mar 31, 2025 | — | — | -1.90 | — | — | 2025-05-12 |
| Dec 31, 2024 | — | — | — | — | — | 2025-03-03 |
| Sep 30, 2024 | — | — | -0.61 | — | — | 2024-11-14 |
| Jun 30, 2024 | — | — | -0.65 | — | — | 2024-08-14 |
| Mar 31, 2024 | — | — | -0.70 | — | — | 2024-05-08 |
| Dec 31, 2023 | — | — | — | — | — | 2025-03-03 |
| Sep 30, 2023 | — | — | -5.52 | — | — | 2024-11-14 |
Questions
When does ArriVent BioPharma report earnings?
ArriVent BioPharma's next earnings report is expected on November 9, 2026.
How did ArriVent BioPharma do last quarter?
In the quarter ended June 2026, ArriVent BioPharma had revenue of —, and diluted EPS of -1.05.
From ArriVent BioPharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.